{"id":15,"date":"2025-03-16T22:21:18","date_gmt":"2025-03-16T21:21:18","guid":{"rendered":"https:\/\/digitalpharma.sk\/sk\/?p=15"},"modified":"2025-03-20T19:12:55","modified_gmt":"2025-03-20T18:12:55","slug":"genova-terapia-predstavuje-novy-pristup-v-liecbe-genetickych-ochoreni","status":"publish","type":"post","link":"https:\/\/digitalpharma.sk\/sk\/blog\/genova-terapia-predstavuje-novy-pristup-v-liecbe-genetickych-ochoreni\/","title":{"rendered":"G\u00e9nov\u00e1 terapia predstavuje nov\u00fd pr\u00edstup v lie\u010dbe genetick\u00fdch ochoren\u00ed"},"content":{"rendered":"\n<p class=\"wp-block-subtitle\">Zolgensma, schv\u00e1len\u00e1 v roku 2019, je prvou g\u00e9novou terapiou na lie\u010dbu spin\u00e1lnej muskul\u00e1rnej atrofie (SMA) a jedn\u00fdm z najdrah\u0161\u00edch liekov na svete.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1440\" height=\"960\" src=\"https:\/\/digitalpharma.sk\/sk\/cms\/wp-content\/uploads\/2025\/03\/aesthetic-background-with-abstract-neon-led-light-effect-1440x960.jpg\" alt=\"\" class=\"wp-image-44\" srcset=\"https:\/\/digitalpharma.sk\/sk\/cms\/wp-content\/uploads\/2025\/03\/aesthetic-background-with-abstract-neon-led-light-effect-1440x960.jpg 1440w, https:\/\/digitalpharma.sk\/sk\/cms\/wp-content\/uploads\/2025\/03\/aesthetic-background-with-abstract-neon-led-light-effect-1536x1024.jpg 1536w, https:\/\/digitalpharma.sk\/sk\/cms\/wp-content\/uploads\/2025\/03\/aesthetic-background-with-abstract-neon-led-light-effect-2048x1365.jpg 2048w\" sizes=\"auto, (max-width: 1440px) 100vw, 1440px\" \/><\/figure>\n\n\n\n<h1 class=\"wp-block-h1\">Ako Zolgensma funguje?<\/h1>\n\n\n\n<p>Zolgensma je zalo\u017een\u00e1 na adeno-asociovanom v\u00edruse (AAV), ktor\u00fd dod\u00e1va funk\u010dn\u00fa k\u00f3piu ch\u00fdbaj\u00faceho g\u00e9nu SMN1 do buniek pacienta. Na rozdiel od be\u017en\u00fdch liekov, Zolgensma je jednorazov\u00e1 inf\u00fazia, ktor\u00e1 poskytuje dlhodob\u00fd terapeutick\u00fd efekt.<\/p>\n\n\n\n<h1 class=\"wp-block-h1\">Farmakoekonomick\u00fd dopad Zolgensmy<\/h1>\n\n\n\n<p>Zolgensma predstavuje prelomov\u00fa g\u00e9nov\u00fa terapiu, no jej vysok\u00e1 cena a finan\u010dn\u00e9 dopady na zdravotn\u00e9 syst\u00e9my vyvol\u00e1vaj\u00fa mno\u017estvo diskusi\u00ed:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Vysok\u00e9 n\u00e1klady<\/strong> \u2013 Cena Zolgensmy presahuje 2 mili\u00f3ny USD za jednorazov\u00fa d\u00e1vku, \u010do ju rad\u00ed medzi najdrah\u0161ie lieky na svete.<\/li>\n\n\n\n<li><strong>Dlhodob\u00e1 \u00faspora<\/strong> \u2013 Napriek vysok\u00fdm po\u010diato\u010dn\u00fdm n\u00e1kladom sa predpoklad\u00e1, \u017ee g\u00e9nov\u00e1 terapia m\u00f4\u017ee zn\u00ed\u017ei\u0165 celo\u017eivotn\u00e9 v\u00fddavky na starostlivos\u0165 o pacientov so SMA.<\/li>\n\n\n\n<li><strong>Dostupnos\u0165 a hradenie<\/strong> \u2013 V niektor\u00fdch krajin\u00e1ch je Zolgensma hraden\u00e1 zo zdravotn\u00e9ho poistenia, no pr\u00edstup k lie\u010dbe z\u00e1vis\u00ed od individu\u00e1lnych rozhodnut\u00ed pois\u0165ovn\u00ed a \u0161t\u00e1tov.<\/li>\n\n\n\n<li><strong>Etick\u00e9 a soci\u00e1lne ot\u00e1zky<\/strong> \u2013 Vysok\u00e1 cena Zolgensmy vyvol\u00e1va diskusie o spravodlivosti pr\u00edstupu k modern\u00fdm lie\u010dbam a o tom, ako by zdravotn\u00e9 syst\u00e9my mali pristupova\u0165 k drah\u00fdm inov\u00e1ci\u00e1m.<\/li>\n<\/ol>\n\n\n\n<h1 class=\"wp-block-h1\">Bud\u00facnos\u0165 g\u00e9novej terapie<\/h1>\n\n\n\n<p>G\u00e9nov\u00e1 terapia ako Zolgensma nazna\u010duje bud\u00facnos\u0165 lie\u010dby genetick\u00fdch ochoren\u00ed. V\u00fdzvou v\u0161ak zost\u00e1va jej financovanie, udr\u017eate\u013enos\u0165 a regul\u00e1cia cien, aby bola dostupn\u00e1 \u010do naj\u0161ir\u0161iemu spektru pacientov.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zolgensma je zalo\u017een\u00e1 na adeno-asociovanom v\u00edruse (AAV), ktor\u00fd dod\u00e1va funk\u010dn\u00fa k\u00f3piu ch\u00fdbaj\u00faceho g\u00e9nu SMN1 do buniek pacienta. Na rozdiel od be\u017en\u00fdch liekov, Zolgensma je jednorazov\u00e1 inf\u00fazia, ktor\u00e1 poskytuje dlhodob\u00fd terapeutick\u00fd efekt. Zolgensma predstavuje prelomov\u00fa g\u00e9nov\u00fa terapiu, no jej vysok\u00e1 cena a finan\u010dn\u00e9 dopady na zdravotn\u00e9 syst\u00e9my vyvol\u00e1vaj\u00fa mno\u017estvo diskusi\u00ed: G\u00e9nov\u00e1 terapia ako Zolgensma nazna\u010duje bud\u00facnos\u0165 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":44,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-inovacie"],"_links":{"self":[{"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/posts\/15","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/comments?post=15"}],"version-history":[{"count":8,"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/posts\/15\/revisions"}],"predecessor-version":[{"id":46,"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/posts\/15\/revisions\/46"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/media\/44"}],"wp:attachment":[{"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/media?parent=15"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/categories?post=15"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digitalpharma.sk\/sk\/wp-json\/wp\/v2\/tags?post=15"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}